Teva Pays $420 Million to End Generic-Drug Securities Suit (1)
Teva Pharmaceutical reports 5% fall in Q4 2022 revenue
Teva CEO stands down during troubled times - MedCity News
Teva Stock Plunges On Flat Sales, Earnings Disappointment | Investor's Business Daily
Teva to pay New York $500M for role in opioid crisis - POLITICO
Teva Pharmaceuticals, NY reach opioid lawsuit settlements worth $523M - Top Class Actions
Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum | AlphaStreet
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment? - Simply Wall St News
Teva Rockets After Hiring Former Novo Nordisk Exec As CEO | Investor's Business Daily
Teva profit plummets, stock slides | Ctech
Here's Why Teva Pharma Stock Is Soaring Today
Should You Sell Teva Pharmaceutical Industries Ltd (TEVA) Stock Friday Morning?
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Teva announces $519 million FCPA settlement | The FCPA Blog
Teva Pharmaceuticals at heart of major price fixing suit in US - www.israelhayom.com
Teva Pharmaceutical: Slow Road To A Higher Share Price (NYSE:TEVA) | Seeking Alpha
Layoffs To Deepen As Teva Unveils New Structure And Leadership Changes - Pharmaceutical Processing World
Teva Pharmaceutical Industries says it'll close Bucks Co. plant in 2017 | Business News | wfmz.com
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva shares surge after announcing global opioid settlement
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva Announces Launch of $2 Billion (Equivalent) Offering of Sustainability-Linked Senior Notes - ESG News
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
A Drug Company Wagers the U.S. Won't Dare Charge It With Crimes - The New York Times
Teva Pharmaceuticals (@TevaUSA) / Twitter
